A federal judge blocked the Pentagon's Chinese military designation of WuXi AppTec, finding the DoD's case rested on a misreading. Plus: Sionna Therapeutics' cystic fibrosis failure sends shares down ninety-two percent and leaves Vertex Pharmaceuticals' Trikafta franchise uncontested; BridgeBio's Attruby beats consensus at $222 million as the ATTR-cardiomyopathy market tilts stabilizer-first against Alnylam's Amvuttra; Tenax Therapeutics' oral levosimendan misses in PH-HFpEF; Vaderis raises $152 million for engasertib in hereditary hemorrhagic telangiectasia; and AbbVie, Novartis and Bristol Myers Squibb sue Illinois over 340B. Visit us at thepharmacloseout.com.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →